Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 May;23(5):511–521. doi: 10.1111/j.1365-2125.1987.tb03086.x

Adimolol, a long acting beta-adrenoceptor blocker in man.

H L Elliott, C R Jones, N M Deighton, P A Meredith, J L Reid
PMCID: PMC1386186  PMID: 2885022

Abstract

A comparative study in eight healthy normotensive males of the effects on blood pressure, heart rate and beta-adrenoceptor function following single oral doses of adimolol (600 mg), propranolol (240 mg) and placebo. Both active treatments produced small but significant reductions in blood pressure and heart rate, supine and erect. These effects persisted for up to 7 days after adimolol. The heart rate increases following both dynamic exercise and intravenous isoprenaline were attenuated by both propranolol and adimolol. With adimolol evidence of functional beta-adrenoceptor antagonism was sustained for up to 7 days. Lymphocyte beta-adrenoceptor binding studies showed that both adimolol and propranolol significantly reduced affinity for beta-adrenoceptors. In addition, adimolol significantly reduced receptor number and even by 3 days after dosing Bmax had only returned to half the control value. In a small sub-group of subjects there was no evidence to suggest that adimolol had additional alpha-adrenoceptor antagonist properties. Adimolol was detected in plasma for up to 3 days after dosing. The mean terminal elimination half-life was 14 h, compared to 3 h for propranolol. This study confirms that adimolol has prolonged beta-adrenoceptor antagonist activity with effects persisting for up to 7 days after a single dose. The reduction in beta-adrenoceptor number following adimolol suggests that this prolonged effect may not be solely due to competitive antagonism but may additionally depend upon non-competitive antagonism at beta-adrenoceptors.

Full text

PDF
511

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarons R. D., Nies A. S., Gal J., Hegstrand L. R., Molinoff P. B. Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest. 1980 May;65(5):949–957. doi: 10.1172/JCI109781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  3. Boxenbaum H. G., Riegelman S., Elashoff R. M. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974 Apr;2(2):123–148. doi: 10.1007/BF01061504. [DOI] [PubMed] [Google Scholar]
  4. Brodde O. E., Engel G., Hoyer D., Bock K. D., Weber F. The beta-adrenergic receptor in human lymphocytes: subclassification by the use of a new radio-ligand, (+/-)-125 Iodocyanopindolol. Life Sci. 1981 Nov 23;29(21):2189–2198. doi: 10.1016/0024-3205(81)90490-2. [DOI] [PubMed] [Google Scholar]
  5. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  6. Giudicelli Y., Lacasa D., Agli B., Leneveu A. Comparison of changes in the characteristics of beta-adrenoceptors and responsiveness of human circulating lymphocytes during and after chronic administration of pindolol and propranolol. Eur J Clin Pharmacol. 1984;26(1):7–12. doi: 10.1007/BF00546700. [DOI] [PubMed] [Google Scholar]
  7. Kerry R., Scrutton M. C. Platelet beta-adrenoceptors. Br J Pharmacol. 1983 Jul;79(3):681–691. doi: 10.1111/j.1476-5381.1983.tb10005.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  9. McDevitt D. G., Shand D. G. Plasma concentrations and the time-course of beta blockade due to propranolol. Clin Pharmacol Ther. 1975 Dec;18(6):708–713. doi: 10.1002/cpt1975186708. [DOI] [PubMed] [Google Scholar]
  10. Molinoff P. B., Aarons R. D. Effects of drugs on beta-adrenergic receptors on human lymphocytes. J Cardiovasc Pharmacol. 1983;5 (Suppl 1):S63–S67. doi: 10.1097/00005344-198300051-00010. [DOI] [PubMed] [Google Scholar]
  11. Molinoff P. B., Aarons R. D., Nies A. S., Gerber J. G., Wolfe B. B., Goens M. B. Effects of pindolol and propranolol on beta-adrenergic receptors on human lymphocytes. Br J Clin Pharmacol. 1982;13(Suppl 2):365S–365S. doi: 10.1111/j.1365-2125.1982.tb01942.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Riddell J. G., Harron D. W., Shanks R. G. Comparative effects of adimolol, labetalol and propranolol on heart rate and blood pressure in man. Br J Clin Pharmacol. 1985 Apr;19(4):405–410. doi: 10.1111/j.1365-2125.1985.tb02662.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sumner D. J., Elliott H. L., Reid J. L. Analysis of the pressor dose response. Clin Pharmacol Ther. 1982 Oct;32(4):450–458. doi: 10.1038/clpt.1982.188. [DOI] [PubMed] [Google Scholar]
  14. Wellstein A., Palm D., Belz G. G., Pitschner H. F. Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockers. Arzneimittelforschung. 1985;35(1):2–6. [PubMed] [Google Scholar]
  15. Wellstein A., Palm D., Pitschner H. F., Belz G. G. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Clin Pharmacol. 1985;29(2):131–147. doi: 10.1007/BF00547412. [DOI] [PubMed] [Google Scholar]
  16. Wiedemann I. High-performance liquid chromatographic determination of MEN 935 in human plasma, a highly specific and sensitive analytical method for a new antihypertensive drug. Arzneimittelforschung. 1983;33(6):861–864. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES